EUVIMEDEUVIMED entdecken
Studienprotokoll

L26/O-142 Progestin-primed ovarian stimulation versus gonadotropin-releasing hormone antagonist protocol in intracytoplasmic sperm injection cycles in patients with diminished ovarian reserve: a prospective randomized study

G. Oner, E. Karaman

Human Reproduction · 01.07.2026 · 41 (Supplement_1)

DOI: 10.1093/humrep/deag083.142 ↗

Kurz gefasst

Studienprotokoll in der Zeitschrift Human Reproduction, online erschienen am 08.07.2026. Verfasst von G. Oner und 1 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Study question Which is the better ovarian stimulation strategy for women with diminshed ovarian reserve (DOR), progestin primed ovarian stimulation (PPOS) or Gonadotropin-Releasing Hormone (GnRH) Antagonist? Summary answer This prospective randomized trial represents that, GnRH-antagonist protocol provides a higher oocyte retrieval and embryo yield in the women with DOR compared with PPOS . What is known already Initial studies primarily involving general IVF populations and oocyte-donation cycles, have shown that PPOS effectively prevents premature ovulation while maintaining embryological outcomes comparable to conventional protocols. Despite these promising findings, a significant evidence gap persists regarding the efficacy and clinical applicability of PPOS in women with confirmed DOR. The current literature predominantly consists of retrospective analyses or small-scale investigations. Importantly, high-quality prospective randomized controlled trials (RCTs) directly comparing PPOS with the GnRH-antagonist protocol in a clearly defined DOR cohort remain scarce. Study design, size, duration In this prospective randomized controlled trial, 226 women with DOR were allocated to either PPOS (n = 113) or GnRH-antagonist (n = 113) protocols. The primary outcome was the number of mature metaphase II (MII) oocytes retrieved. Secondary outcomes included total oocyte yield, fertilization rate, blastulation rate, clinical pregnancy rate, ongoing pregnancy rate, and embryo freezing rate. The study was performed between February 2025 and August 2025. Participants/materials, setting, methods Participants were selected consecutively from those presenting to the reproductive medicine unit and screened for eligibility based on predefined clinical criteria for DOR. Inclusion Criteria • Women aged 20–45 years • Diagnosis of DOR based on the Poseidon 3-4 criteria • Undergoing their first or second ICSI cycle Exclusion Criteria • Severe male-factor infertility requiring surgical sperm retrieval • Congenital or acquired uterine anomalies • Untreated endocrine disorders (e.g., thyroid dysfunction, hyperprolactinemia) • Previous profound hypo-response to ovarian stimulation • Any contraindication to exogenous gonadotropin administration. Main results and the role of chance The GnRH-antagonist protocol resulted in a significantly higher yield of total oocytes (3.81 vs 1.79, p < 0.001) and MII oocytes (1.70 vs 1.23, p < 0.001) compared to the PPOS protocol. Embryo development was more favorable in the GnRH-antagonist group, with a significantly greater number of blastocysts (1.23 vs 0.64, p < 0.001) and a higher embryo freezing rate (36.3% vs 19.5%, p = 0.004). However, no significant differences were observed between the two groups in fertilization, clinical pregnancy (p = 0.328) and ongoing pregnancy (p = 0.408). A notable finding was the significantly higher rate of embryo cryopreservation in the antagonist group (36.3% vs 19.5%, χ²=8.123, p = 0.004), reflecting the superior embryo yield observed in this protocol. Cycle cancellation rates were lower in the antagonist group (4.4% vs 7.1%), though this difference was not statistically significant. Limitations, reasons for caution The strict application of Poseidon criteria ensured a homogenous patient population with confirmed diminished ovarian reserve, increasing the clinical relevance of the results. The single-center design may limit the external validity of the findings, and although the sample size was adequate for primary outcomes. Wider implications of the findings This prospective randomized study demonstrates that the GnRH-antagonist protocol provides significant benefits to women with DOR compared to PPOS. The key value of GnRH-antagonist protocol lies in its markedly higher embryo cryopreservation rate, offering greater strategic flexibility for cumulative pregnancy success. Thus, GnRH-antagonist protocol is a highly effective and valuable. Trial registration number Yes

Zitieren

APA

Oner, G., & Karaman, E. (2026). L26/O-142 Progestin-primed ovarian stimulation versus gonadotropin-releasing hormone antagonist protocol in intracytoplasmic sperm injection cycles in patients with diminished ovarian reserve: a prospective randomized study. Human Reproduction, 41(Supplement_1). https://doi.org/10.1093/humrep/deag083.142

Vancouver

Oner G, Karaman E. L26/O-142 Progestin-primed ovarian stimulation versus gonadotropin-releasing hormone antagonist protocol in intracytoplasmic sperm injection cycles in patients with diminished ovarian reserve: a prospective randomized study. Human Reproduction. 2026;41(Supplement_1). doi:10.1093/humrep/deag083.142

BibTeX
@article{Oner2026,
  author = {Oner, G. and Karaman, E.},
  title = {L26/O-142 Progestin-primed ovarian stimulation versus gonadotropin-releasing hormone antagonist protocol in intracytoplasmic sperm injection cycles in patients with diminished ovarian reserve: a prospective randomized study},
  journal = {Human Reproduction},
  year = {2026},
  volume = {41},
  number = {Supplement_1},
  doi = {10.1093/humrep/deag083.142}
}
Kostenlos starten →